作者: Jay P. Ciezki , Eric A. Klein , Kenneth Angermeier , James Ulchaker , Nabil Chehade
DOI: 10.1016/J.IJROBP.2004.05.067
关键词:
摘要: Purpose To examine the value of androgen deprivation (AD) in curative treatment low- and intermediate-risk prostate cancer treated with three major modalities: radical retropubic prostatectomy (RRP), external beam radiotherapy (EBRT), permanent implantation (PI). Methods materials During 1996–2001, 1668 patients were at The Cleveland Clinic Foundation. Only a minimum 2 years prostate-specific antigen follow-up included analysis, biochemical relapse-free survival (bRFS) was used as endpoint. Patients grouped according to modality stratified use AD. Results overall 5-year bRFS rate 87.8%. for low-risk 89% 79%. For patients, rates by (without AD vs. AD, respectively) PI: 90% 93%; EBRT: RRP: 84%. 88% 82%; 81% 84%; 75% 72%. None comparisons within risk groups or among modalities supports an increased efficacy Conclusion Five-year are not improved